Deutsche Bank
OCUL icon

Deutsche Bank’s Ocular Therapeutix OCUL Stock Holding History

Deutsche Bank’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.35M Buy
631,741
+41,020
+7% +$391K ﹤0.01% 1264
2025
Q4 		$7.17M Buy
590,721
+278,639
+89% +$3.38M ﹤0.01% 1179
2025
Q3 		$3.65M Buy
312,082
+72,061
+30% +$862K ﹤0.01% 1455
2025
Q2 		$2.23M Sell
240,021
-18,204
-7% -$142K ﹤0.01% 1635
2025
Q1 		$1.89M Sell
258,225
-197,895
-43% -$1.52M ﹤0.01% 1791
2024
Q4 		$3.9M Sell
456,120
-377,454
-45% -$3.68M ﹤0.01% 1455
2024
Q3 		$7.25M Buy
833,574
+26,264
+3% +$216K ﹤0.01% 1126
2024
Q2 		$5.52M Buy
807,310
+9,782
+1% +$60.4K ﹤0.01% 1210
2024
Q1 		$7.26M Buy
797,528
+762,889
+2,202% +$5.41M ﹤0.01% 1135
2023
Q4 		$154K Sell
34,639
-1,167
-3% -$3.45K ﹤0.01% 3008
2023
Q3 		$112K Buy
35,806
+5,964
+20% +$24.4K ﹤0.01% 3109
2023
Q2 		$154K Sell
29,842
-21,233
-42% -$126K ﹤0.01% 3036
2023
Q1 		$269K Buy
51,075
+16,178
+46% +$76.8K ﹤0.01% 2854
2022
Q4 		$98.1K Buy
34,897
+515
+1% +$1.71K ﹤0.01% 3331
2022
Q3 		$143K Sell
34,382
-5,146
-13% -$25.9K ﹤0.01% 3146
2022
Q2 		$159K Sell
39,528
-5,255
-12% -$19.9K ﹤0.01% 3296
2022
Q1 		$222K Sell
44,783
-4,702
-10% -$26.1K ﹤0.01% 3204
2021
Q4 		$344K Sell
49,485
-1,975
-4% -$15.3K ﹤0.01% 3065
2021
Q3 		$514K Sell
51,460
-5,067
-9% -$56.9K ﹤0.01% 3008
2021
Q2 		$802K Buy
56,527
+3,605
+7% +$54.8K ﹤0.01% 2915
2021
Q1 		$868K Sell
52,922
-8,375
-14% -$161K ﹤0.01% 2753
2020
Q4 		$1.27M Sell
61,297
-100,236
-62% -$1.49M ﹤0.01% 2283
2020
Q3 		$1.23M Buy
161,533
+54,760
+51% +$454K ﹤0.01% 2064
2020
Q2 		$890K Buy
106,773
+92,128
+629% +$611K ﹤0.01% 2298
2020
Q1 		$73K Sell
14,645
-703
-5% -$3.47K ﹤0.01% 3380
2019
Q4 		$59K Buy
15,348
+3,652
+31% +$12.7K ﹤0.01% 3890
2019
Q3 		$34K Sell
11,696
-16,099
-58% -$72K ﹤0.01% 4113
2019
Q2 		$120K Sell
27,795
-15,243
-35% -$56.4K ﹤0.01% 4115
2019
Q1 		$168K Buy
43,038
+2,677
+7% +$10.8K ﹤0.01% 4087
2018
Q4 		$159K Sell
40,361
-35,648
-47% -$196K ﹤0.01% 3996
2018
Q3 		$522K Buy
76,009
+13,517
+22% +$84.8K ﹤0.01% 3761
2018
Q2 		$422K Buy
62,492
+24,764
+66% +$170K ﹤0.01% 3929
2018
Q1 		$243K Sell
37,728
-12,337
-25% -$69.4K ﹤0.01% 4088
2017
Q4 		$221K Buy
50,065
+29,938
+149% +$153K ﹤0.01% 3985
2017
Q3 		$122K Sell
20,127
-102,862
-84% -$662K ﹤0.01% 4100
2017
Q2 		$1.14M Sell
122,989
-10,688
-8% -$103K ﹤0.01% 2939
2017
Q1 		$1.24M Buy
133,677
+11,785
+10% +$98.1K ﹤0.01% 2511
2016
Q4 		$1.02M Buy
121,892
+20,931
+21% +$162K ﹤0.01% 2688
2016
Q3 		$693K Sell
100,961
-27,226
-21% -$166K ﹤0.01% 3039
2016
Q2 		$634K Buy
128,187
+28,558
+29% +$283K ﹤0.01% 3148
2016
Q1 		$961K Sell
99,629
-732
-0.7% -$5.54K ﹤0.01% 2833
2015
Q4 		$938K Sell
100,361
-135
-0.1% -$1.46K ﹤0.01% 2913
2015
Q3 		$1.41M Buy
100,496
+961
+1% +$19.3K ﹤0.01% 2716
2015
Q2 		$2.09M Buy
99,535
+968
+1% +$24K ﹤0.01% 2421
2015
Q1 		$4.14M Buy
98,567
+2,209
+2% +$72.6K ﹤0.01% 1919
2014
Q4 		$2.27M Sell
96,358
-3,644
-4% -$61.3K ﹤0.01% 2581
2014
Q3 		$1.5M Buy
+100,002
New +$1.48M ﹤0.01% 2721

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deutsche Bank's OCUL Position: Q1 2026 in Review

Deutsche Bank increased its Ocular Therapeutix (OCUL) stake by 6.9% in Q1 2026, buying an estimated $391K and bringing the position to 631,741 shares worth $5.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1264.

Deutsche Bank first reported a position in OCUL in Q3 2014 and has held it in 47 quarters since. The position peaked at $7.26M in Q1 2024. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Deutsche Bank held 631,741 shares of Ocular Therapeutix worth $5.35M as of Q1 2026.
  • Deutsche Bank bought 41,020 Ocular Therapeutix shares in Q1 2026, an estimated $391K.
  • Ocular Therapeutix made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1264 holding.
  • Deutsche Bank first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 47 quarters since.
  • Deutsche Bank's Ocular Therapeutix position peaked at $7.26M in Q1 2024.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.